Literature DB >> 19734730

Factors associated with recurrent hospital admissions for gout: a case-control study.

Ingrid Hutton1, Greg Gamble, Peter Gow, Nicola Dalbeth.   

Abstract

OBJECTIVE: Although gout has recognized prevention and treatment options, some patients have recurrent unplanned hospital admissions with gout flares. The aim of this study was to identify factors associated with recurrent hospital admissions with gout.
METHODS: A 1:1 case-control study was designed; cases were patients with 2 or more gout-related hospital admissions during any 12-month period between 2002 and 2007 (n = 48). Each case was matched with an age, sex and ethnicity-matched control patient with gout but without hospital admission, identified from the rheumatology clinic (n = 48).
RESULTS: Patients with recurrent hospital admissions had a higher number of comorbid medical conditions, particularly higher rates of heart disease (odds ratio 2.9, P = 0.013). Cases also had more hospital admissions for other medical problems (mean number of admissions in the preceding year 5.8 vs. 0.6, P < 0.0001). Although cases had higher rates of tophaceous disease and higher serum urate concentrations, there was no difference in gout disease duration. Cases were less likely to be on allopurinol (odds ratio 0.06, P < 0.0001), and those on allopurinol were on lower doses (median dose 200 mg/d vs. 300 mg/d, P = 0.0019).
CONCLUSION: Medical comorbidity, hyperuricemia, and inadequate allopurinol use are associated with repeated unplanned hospitalization for gout. These data suggest that the use of intensive urate-lowering therapy may prevent such admissions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19734730     DOI: 10.1097/RHU.0b013e3181b562f8

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  16 in total

Review 1.  Risk factors for gout and prevention: a systematic review of the literature.

Authors:  Jasvinder A Singh; Supriya G Reddy; Joseph Kundukulam
Journal:  Curr Opin Rheumatol       Date:  2011-03       Impact factor: 5.006

Review 2.  Urate-lowering therapy: current options and future prospects for elderly patients with gout.

Authors:  Lisa K Stamp; Peter T Chapman
Journal:  Drugs Aging       Date:  2014-11       Impact factor: 3.923

Review 3.  Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications.

Authors:  Sebastian E Sattui; Angelo L Gaffo
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-05-02       Impact factor: 5.346

Review 4.  Inpatient gout: a review.

Authors:  Mark C Fisher; Michael H Pillinger; Robert T Keenan
Journal:  Curr Rheumatol Rep       Date:  2014-11       Impact factor: 4.592

Review 5.  Screening for hyperuricaemia and gout: a perspective and research agenda.

Authors:  Lisa Stamp; Nicola Dalbeth
Journal:  Nat Rev Rheumatol       Date:  2014-08-19       Impact factor: 20.543

6.  Time Trends, Predictors, and Outcome of Emergency Department Use for Gout: A Nationwide US Study.

Authors:  Jasvinder A Singh; Shaohua Yu
Journal:  J Rheumatol       Date:  2016-05-01       Impact factor: 4.666

7.  Fingolimod Phosphate (FTY720-P) Activates Protein Phosphatase 2A in Human Monocytes and Inhibits Monosodium Urate Crystal-Induced Interleukin-1β Production.

Authors:  Marwa Qadri; Sandy ElSayed; Khaled A Elsaid
Journal:  J Pharmacol Exp Ther       Date:  2020-11-25       Impact factor: 4.030

8.  Rhazes' prescriptions in treatment of gout.

Authors:  S Changizi Ashtiyani; A Golestanpour; M Shamsi; S M Tabatabaei; M Ramazani
Journal:  Iran Red Crescent Med J       Date:  2012-02-01       Impact factor: 0.611

9.  Hospital admission risk stratification of patients with gout presenting to the emergency department.

Authors:  Wang Han; Nur Azizah Allameen; Irwani Ibrahim; Preeti Dhanasekaran; Feng Mengling; Manjari Lahiri
Journal:  Clin Rheumatol       Date:  2022-01-01       Impact factor: 3.650

10.  Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Administration of Verinurad and Febuxostat in Healthy Male Volunteers.

Authors:  Jesse Hall; Michael Gillen; Xiaojuan Yang; Zancong Shen
Journal:  Clin Pharmacol Drug Dev       Date:  2018-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.